Tag: psychedelics

Arizona’s Democratic Governor Vetoes Bill To Legalize Psilocybin Service Centers

The Democratic governor of Arizona has vetoed a bill to legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting.

Less than a week after lawmakers gave final approval to the legislation, Gov. Katie Hobbs (D) rejected it on Tuesday, arguing that while the psychedelic may hold therapeutic potential, “we do not yet have the evidence needed to support widespread clinical expansion.”

“Arizonans with depression and PTSD deserve access to treatments that may be seen as outside the mainstream, but they should not be the subject of experiments for unproven therapies with a lack of appropriate guardrails,” the governor said in a veto message.

She also said that the bill’s estimated cost is $400,000 per year, which wasn’t accounted for in the budget.

Under the now-vetoed legislation, the Department of Human Services (DHS) would have been authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could have administered the psychedelic.

The measure would have significantly expanded on Arizona’s existing research-focused psychedelics law that provides $5 million in annual funding to support studies into psilocybin therapy.

Hobbs cited that research funding in her statement, saying the goal is to “ensure that those who seek psilocybin treatment are doing so confidently and safely under proper supervision of qualified professionals with documented and verified research to support the treatment.”

She said that money “will be allowed to continue with this year’s budget,” with a separate funding bill she signed into law on Tuesday protecting those dollars, which are exempt from lapsing appropriations provisions.

The vetoed proposal, meanwhile, would have established an Arizona Psilocybin Advisory Board, comprised of members appointed by the governor and legislative leaders. Representatives of the attorney general’s office and DHS, as well as military veterans, first responders, scientists with experience with psilocybin and physicians would have been among the members.

The board would have been responsible for establishing training criteria for psilocybin service center staff, making recommendations on the implementation of the law, and studying the science and policy developments related to psychedelics.

Sen. T. J. Shope (R), the bill’s sponsor, told The Center Square that the veto is a “disappointing result after months of hard work and the overwhelming bipartisan support this received in both houses of the Legislature this year.”

The senator added that if lawmakers were still in session, he’d be pushing for a vote to override the veto, but he’ll have to “settle for trying again next year.”

Keep reading

House Passes Veterans-Focused Marijuana And Psychedelics Amendments

The U.S. House of Representatives has approved amendments to a large-scale spending bill that would authorize U.S. Department of Veterans Affairs (VA) doctors to issue medical marijuana recommendations to military veterans and support psychedelics research and access.

One day after the Rules Committee cleared the proposals for floor consideration, the full chamber adopted them as part of appropriations legislation covering Military Construction, Veterans Affairs and Related Agencies (MilConVA) in a series of votes on Tuesday.

The cannabis measure passed in a vote of 290-116, while the two psychedelics proposals were adopted on voice votes.

One of the accepted proposals from Reps. Brian Mast (R-FL), Earl Blumenauer (D-OR), Barbara Lee (D-CA) and Dave Joyce (R-OH)—who together are the co-chairs of the Congressional Cannabis Caucus—would allow veterans to access state medical marijuana programs and eliminate a VA directive barring the department’s doctors from issuing cannabis recommendations.

SEC. 419. None of the funds appropriated or other wise made available to the Department of Veterans Affairs in this Act may be used to enforce Veterans Health Directive 1315 as it relates to—

(1) the policy stating that ‘‘VHA providers are prohibited from completing forms or registering Veterans for participation in a State-approved marijuana program’’;

(2) the directive for the ‘‘Deputy Under Secretary for Health for Operations and Management’’ to ensure that ‘‘medical facility Directors are aware that it is VHA policy for providers to assess Veteran use of marijuana but providers are prohibited from recommending, making referrals to or completing paperwork for Veteran participation in State marijuana programs’’; and

(3) the directive for the ‘‘VA Medical Facility Director’’ to ensure that ‘‘VA facility staff are aware of the following’’ ‘‘[t]he prohibition on recommending, making referrals to or completing forms and registering Veterans for participation in State approved marijuana programs’’.

“My proposed amendment, I believe, is common sense. It allows doctors in the VA—those that deal with veterans—to give advice to their veteran patients,” Mast said on the floor. “That seems simple enough, but under the status quo, VA doctors are limited in essential treatment options that they can offer to their patients and treatments that patients that are not veterans can readily assess in many states.”

“Beyond the veteran population, the nation is turning the page on how we think about cannabis. It’s become a key part of the medical system in more than 30 states. It offers law-abiding Americans a low-cost and safe option,” he said. “Do not keep those who’ve fought for our country from accessing what’s proven to be a critical tool for pain management. It is time for change. Veterans deserve to have access to every possible tool, and the best medical options available and the best possible medical advice by their doctors.”

Keep reading

DEA Exemption Process For Religious Psychedelics Use Needs Clearer Timelines And Standards, Government Watchdog Agency Says

A federal government watchdog agency says in a new report that the Drug Enforcement Administration should improve the process through which it considers granting religious exemptions for psilocybin and other controlled substances, asserting that the existing route lacks clarity on timing, evaluation and other matters.

The 80-page report from the U.S. Government Accountability Office (GAO) notes that although psilocybin remains a Schedule I controlled substance under the Controlled Substances Act (CSA), people may petition DEA for exemptions to use it—or other controlled substances—for religious purposes.

“DEA has established a process for these petitions, but its guidance doesn’t set clear timeframes for the decision-making,” it continues. “Exemption petitions have taken from 8 months to over 3 years to be resolved.”

GAO focused specifically on psilocybin use under the Religious Freedom Restoration Act (RFRA), which is meant to protect religious practices from undue government burdens. The agency found that the DEA exemption procedure itself was burdensome.

“Selected stakeholders reported several barriers to the legal access and use of psilocybin for religious practices under the Religious Freedom Restoration Act,” GAO says. “For example, DEA established a process for parties to petition for a religious exemption from the Controlled Substances Act to use controlled substances for religious purposes. However, DEA’s guidance does not inform petitioners on its timeframes to make determinations on completed petitions.”

Keep reading

Atlanta Could Add Psilocybin And Ketamine To City Workers’ Healthcare Plans Under Pending Resolution

A new proposal from an Atlanta City Council member would direct municipal officials to explore the pros and cons of adding coverage for psilocybin and ketamine as mental health treatments to the city’s healthcare plan for firefighters, police and other government workers.

“Traditional treatments for mental illnesses such as depression, anxiety, PTSD, and others have shown limited effectiveness for some individuals, leading to a need for exploring alternative therapeutic options,” the legislation, which is currently being sponsored by 11 of the Council’s 16 members, states. “Recent research has demonstrated the potential efficacy of alternative therapies such as ketamine-assisted therapy and psilocybin-assisted therapy in treating various mental health conditions, offering promising results where other treatments have failed.”

The resolution’s lead sponsor, Councilmember Liliana Bakhtiari, has said city workers deserve access to a broad range of mental health services.

“We should be offering our employees—and especially our first responders, who are expected to be superhuman—the same amount of grace and providing them with a tool set to essentially overcome this issue,” The lawmaker recently told Axios.

Bakhtiari said the impetus for including the drugs on public employees’ health plans was meeting a West Virginia police officer who witnessed a fellow officer die of suicide and later used ketamine to treat his PTSD. The lawmaker said they’re not aware of any other city governments that have looked into covering psilocybin or ketamine treatment.

The resolution from Bakhtiari would request the Atlanta’s human resources department to “explore the feasibility of adding coverage for ketamine therapy, psilocybin therapy, and other alternative therapies for mental illness in the City’s employee benefits contract during its next round of negotiations.”

Keep reading

Chemical tweaks to a toad hallucinogen turns it into a potential drug

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing hallucinations. They act by binding to a serotonin receptor. But there are 14 known types of serotonin receptors, and most of the research into these compounds has focused on only one of them—the one these molecules like, called 5-HT2A. (5-HT, short for 5-hydroxytryptamine, is the chemical name for serotonin.)

The Colorado River toad (Incilius alvarius), also known as the Sonoran Desert toad, secretes a psychedelic compound that likes to bind to a different serotonin receptor subtype called 5-HT1A. And that difference may be the key to developing an entirely distinct class of antidepressants.

Uncovering novel biology

Like other psychedelics, the one the toad produces decreases depression and anxiety and induces meaningful and spiritually significant experiences. It has been used clinically to treat vets with post-traumatic stress disorder and is being developed as a treatment for other neurological disorders and drug abuse. 5-HT1A is a validated therapeutic target, as approved drugs, including the antidepressant Viibryd and the anti-anxiety med Buspar, bind to it. But little is known about how psychedelics engage with this receptor and which effects it mediates, so Daniel Wacker’s lab decided to look into it.

The researchers started by making chemical modifications to the frog psychedelic and noting how each of the tweaked molecules bound to both 5-HT2A  and 5-HT1A. As a group, these psychedelics are known as “designer tryptamines”—that’s tryp with a “y”, mind you—because they are metabolites of the amino acid tryptophan.

The lab made 10 variants and found one that is more than 800-fold selective about sticking to 5-HT1A as compared to 5-HT2A. That makes it a great research tool for elucidating the structure-activity relationship of the 5-HT1A receptor, as well as the molecular mechanisms behind the pharmacology of the drugs on the market that bind to it. The lab used it to explore both of those avenues. However, the variant’s ultimate utility might be as a new therapeutic for psychiatric disorders, so they tested it in mice.

Keep reading

Most Americans Who Have Tried Marijuana Or Psychedelics Had ‘Positive’ Experiences, Survey Finds

A majority of Americans have tried marijuana—and most say they had a positive experience—according to a new poll.

The survey from YouGov also found that one in five Americans have used psilocybin mushrooms, and an even greater majority of those respondents described the experience as positive. Most people who have tried other psychedelics like LSD and MDMA also said it was a good time.

As the federal government moves to reclassify cannabis and more states pursue psychedelics reform, the poll offers fresh insights into how people have personally used the substances and where they stand on changing drug laws.

YouGov asked respondents about four substances: marijuana, psilocybin, LSD and MDMA. By far the most commonly used was marijuana (57 percent), followed by psilocybin (20 percent), LSD (16 percent) and MDMA (11 percent).

For each substance, people who said they’ve used it reported a positive experience, most prominently for psilocybin (65). The rest were roughly equal: marijuana (57 percent), MDMA (56 percent) and LSD (55 percent).

About one and four people who’ve used the drugs described the experience as equally positive and negative. And 20 percent of people who’ve consumed marijuana, LSD or MDMA said it was a negative experience, but only eight percent said the same of psilocybin.

Keep reading

Church of the Eagle and the Condor Can Now Drink Ayahuasca Legally in the US

The prophecy of the Eagle and the Condor has manifested. Following a years-long legal battle, the Church of the Eagle and the Condor has successfully settled with the US Department of Justice (DOJ), the Department of Homeland Security (DHS), Customs and Border Protection (CBP), and the Drug Enforcement Administration (DEA) to legally use ayahuasca as an integral part of its religious practices, according to a press release. 

The Church of the Eagle and the Condor is officially the first non-Christian church to obtain such legal protections. This also marks the first time in history that a church has received federal authorization to import and facilitate ayahuasca without going to trial. This historic settlement has promising implications for other Indigenous-rooted and syncretic faiths hoping to work with entheogens.

“This settlement reaffirms our right to practice our spirituality as we have always known,” says Belinda P. Eriacho, board member of the Church of the Eagle and the Condor, and member of the Diné / A:shwii lineages. “It is a recognition by the US government and an important milestone in honoring and validating Indigenous belief systems.”

Keep reading

Second California Senate Committee Approves Bill To Legalize Psychedelic Service Centers

A second California Senate committee has approved a bill to legalize psychedelic service centers where adults 21 and older could access psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.

About a week after an initial panel cleared the legislation, the Senate Public Safety Committee passed the measure from Sen. Scott Wiener (D) in a 3-2 vote on Tuesday. It next heads to the Appropriations Committee.

The “Regulated Therapeutic Access to Psychedelics Act” has been drafted in a way that’s meant to be responsive to concerns voiced by Gov. Gavin Newsom (D) last year when he vetoed a broader proposal that included provisions to legalize low-level possession of substances such as psilocybin.

Instead, the new bill that’s now being unveiled would provide regulated access to psychedelics in a facilitated setting, without removing criminal penalties for possession outside of that context. It does not lay out any specific qualifying medical conditions that a person must have in order to access the services.

The measure had already undergone a series of mostly technical amendments before reaching committee. Wiener also agreed to revise the legislation at last week’s hearing to make it so psychedelics facilitators would need to have an existing professional health license, such as those for psychiatrists, social workers, drug and alcohol counselors and nurse practitioners.

Keep reading

Colorado Senate Passes Bill That Could Ban Social Media Users Who Post Positively About Drugs—Including Legal Psychedelics

Colorado’s Senate has approved a sweeping social media bill that, among other provisions, could force platforms to ban users for talking positively online about certain controlled substances, such as state-legal psychedelics, certain hemp products and even some over-the-counter cough syrups.

The legislation, SB24-158—a broad proposal concerning internet age verification and content policies—would require social media platforms to immediately remove any user “who promotes, sells, or advertises an illicit substance.”

Initially that provision would have applied to all controlled substances under state law—including state-legal marijuana—but an amendment last month from the bill’s sponsor, Sen. Chris Hansen (D), includes language saying that “a social media platform may allow a user to promote, sell, or advertise medical marijuana or retail marijuana to users who are at least twenty-one years of age” so long as the content complies with state cannabis laws.

The amended legislation would still apply to numerous other legal and illegal substances.

On Wednesday, the Senate voted 30–1 to pass the revised measure on third reading, with four members excused.

Earlier this week, the Senate Appropriations Committee also adopted two amendments to the bill, including one adding staff funding for the state attorney general’s office and another that could make the act subject to voter approval in November.

Critics say even with the marijuana-related amendment, the bill could create major problems for users trying to post benign—and legal—content around substances like cough medicine.

Keep reading

Researchers Ask Federal Court To Block DEA From Banning Two Psychedelics Under ‘Unconstitutional’ Administrative Process

Researchers are asking a federal court to block the Drug Enforcement Administration (DEA) from proceeding in its attempt to ban two psychedelics, arguing that the agency’s administrative approach to the proposed scheduling is unconstitutional.

Panacea Plant Sciences (PPS) filed a complaint and request for injunctive relief against DEA in the U.S. District Court for the Western District of Washington last week.

The legal challenge focuses on the agency’s recent scheduling of an administrative hearing to receive expert input on its controversial plans to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA).

The filing doesn’t speak to the merits of the scheduling proposal—an issue that psychedelics researchers have previously addressed in public comment. Rather, PPS is contesting the administrative hearing process that’s preceding final rulemaking, arguing that DEA’s reliance on administrative law judges (ALJs) to settle such arbitration is unconstitutional based on U.S. Supreme Court precedent.

PPS said that because the Supreme Court has held that ALJs are considered “inferior officers,” current statutory removal protections unconstitutionally insulate them from executive control under Article II of the Constitution. That means DEA should not be permitted to subject researchers to an administrative hearing concerning the psychedelic scheduling proposal, the filing says.

“The hearing and scheduling poses a significant threat to the company,” it says. “PPS conducts research and development on medical technologies which include the use of DOI or DOC for development and as products themselves. Currently, DOI and DOC are not controlled.”

“Under the Controlled Substances Act (CSA) and its implementing regulations, PPS will be required to turn over to law enforcement or destroy our stock of DOI and DOC which means the rule-making acts as an effective taking of property,” the document says.

“As a result, when PPS received the hearing notice from DEA, it was faced with a stark choice: either default and lose automatically or defend itself against the DEA’s attempts to schedule DOI and DOC and its use of an ALJ-overseen adjudication,” it continues. “PPS is thus compelled to participate in the DEA’s adjudicatory proceedings.”

Keep reading